GSK grants 85,714-share award to Chief People Officer

GSK plc granted a 2026 performance-based conditional award of 85,714 shares to its Chief People Officer, vesting over a three-year period.

Rhea-AI Filing Summary

GSK plc (GSK) reported that on September 8, 2026 it granted a conditional share award to Roanne Parry, Chief People Officer and Executive Committee member, under the GlaxoSmithKline 2017 Performance Share Plan. The award covers 85,714 Ordinary Shares of 31¼ pence each, with performance measured over the three financial years from January 1, 2026 to December 31, 2028. Vesting will depend on achievement against performance measures set by the Remuneration Committee, aligned with those of other 2026 Executive Committee awards, and any portion that does not vest at the end of the period will lapse. Dividends will accrue during the performance period but only vest in line with the final vesting outcome.

Key Figures

Conditional award size: 85,714 shares Reference price per share: £18.3750 Nominal value per Ordinary Share: 31.25 pence +3 more

6 metrics

Conditional award size 85,714 shares Number of Ordinary Shares in the conditional award granted September 8, 2026

Reference price per share £18.3750 Price shown in the transaction notification table for the 85,714-share award

Nominal value per Ordinary Share 31.25 pence Ordinary shares of 31¼ pence each described as the underlying instrument

Performance period start January 1, 2026 Beginning of the three-year performance period for the 2026 awards

Performance period end December 31, 2028 End of the three-year performance period for the 2026 awards

Transaction date September 8, 2026 Date the conditional award to Roanne Parry was granted

Key Terms

Performance Share Plan, conditional share award, Person Discharging Managerial Responsibilities, American Depositary Shares, +1 more

5 terms

Performance Share Plan financial

"under the GlaxoSmithKline 2017 Performance Share Plan ('the Plan')"

A performance share plan grants company shares to employees or executives only if the business meets specific targets over a set period, so the reward depends on results rather than being automatic. For investors it matters because it aligns managers’ pay with company performance—like promising a team stock instead of cash if they hit goals—which can influence future share count, shareholder value, and how confidently management pursues growth.

conditional share award financial

"the Company granted a conditional share award to Roanne Parry"

Person Discharging Managerial Responsibilities regulatory

"a Person Discharging Managerial Responsibilities ('PDMR')"

A person discharging managerial responsibilities is an individual who holds a senior role with authority to make or influence a company’s strategic or operational decisions, such as executives, board members, or other top managers. Investors care because these people often have access to confidential information and their buying or selling of company shares must be disclosed—like a referee who knows the score before the crowd, their actions can signal important, non-public insights about a company's prospects.

American Depositary Shares financial

"awards are granted over a specific number of Ordinary Shares or American Depositary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

performance period financial

"The performance period for the awards is the three financial years"

The performance period is the specific time span over which an investment’s results, an employee’s targets, or a fund’s returns are measured and judged. It matters to investors because the length and start/end of that window determine which gains or losses count toward performance fees, bonus payouts, or benchmark comparisons—much like timing a race decides who wins, the chosen period can change whether results look strong or weak.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did GSK (GSK) announce regarding Roanne Parry in this 6-K?

GSK announced that on September 8, 2026 it granted Roanne Parry, Chief People Officer and Executive Committee member, a conditional award of 85,714 Ordinary Shares under the 2017 Performance Share Plan, subject to performance over three financial years.

How many GSK (GSK) shares are included in Roanne Parry’s 2026 Performance Share Plan award?

The conditional award granted to Roanne Parry covers 85,714 Ordinary Shares of 31¼ pence each. The percentage of these shares that will ultimately vest depends on performance against measures set by the Remuneration Committee.

What is the performance period for the GSK (GSK) 2026 award to Roanne Parry?

The performance period for Roanne Parry’s conditional award is three financial years from January 1, 2026 to December 31, 2028. Any part of the award that does not vest at the end of this period will lapse.

What performance measures apply to GSK (GSK) Chief People Officer’s conditional award?

The filing states that the performance measures for Roanne Parry’s award are the same as those for 2026 awards to other Executive Committee members, set by the Remuneration Committee and detailed in an announcement dated February 16, 2026.

How are dividends treated on the GSK (GSK) conditional share award to Roanne Parry?

Dividends will accrue during the performance period on the conditional award of Ordinary Shares but will only vest to the extent that the underlying award vests at the end of the three-year performance period. These dividends are not included in the 85,714-share figure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 10:31 AM EDT Accepted by SEC EDGAR 09/09/2026 - 10:31 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

2026 Performance Share Plan Award - Roanne Parry

2026 Performance Share Plan Award

On 8 September 2026, the Company granted a conditional share award to Roanne Parry, a Person Discharging Managerial Responsibilities ('PDMR'), under the GlaxoSmithKline 2017 Performance Share Plan ('the Plan').

The Plan allows a performance-related opportunity in the form of conditional awards to be granted to senior executives in the Group, including the Executive Directors and other PDMRs. Ms Parry became eligible for the award following her joining GSK as Chief People Officer and an Executive Committee member on 1 May 2026. 

Under the terms of the Plan, conditional awards are granted over a specific number of Ordinary Shares or American Depositary Shares ('ADS'), and the percentage of the award that ultimately vests is dependent on the level of achievement against performance measures set by the Remuneration Committee. The performance measures for Ms Parry's award are the same as those applicable to the 2026 awards granted to other Executive Committee members, as detailed within the announcement of 16 February 2026.

The performance period for the awards is the three financial years from 1 January 2026 to 31 December 2028.

Notes

1.   To the extent that each element of a conditional award does not vest at the end of the three-year performance period, it will lapse.

2.   Ms Parry was granted a conditional award of Ordinary Shares under the terms of the GlaxoSmithKline 2017 Performance Share Plan.

3.   Dividends will accrue on the conditional award of Ordinary Shares during the performance period but will only vest to the extent that the award vests at the end of the performance period. These dividends are not included in the figures below.

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Roanne Parry
b)	Position/status	Chief People Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£18.3750	85,714
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-09-08
f)	Place of the transaction	N/A

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: September 09, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc